Key Takeaways Amneal Pharmaceuticals trades at 1.39x sales, below industry and sector averages.AMRX shares surged 83% in a year, but paused as 2026 Specialty growth slows.AMRX targets $14 on 1.5x sales, tied to launches, margins, and execution.Amneal Pharmaceuticals (AMRX) has built momentum on broad-based growth across generics, Specialty, and its government-focused distribution business. Results in 2025 showed higher revenues, higher earnings, and expanding cash generation, supported by mix improvement an ...

Key Takeaways Amneal Pharmaceuticals gains GLP-1 exposure via a Pfizer-linked manufacturing partnership.AMRX avoids clinical risks, focusing on execution, supply and manufacturing scale.AMRX leverages peptide and injectable capacity to expand into higher-value products.Amneal Pharmaceuticals (AMRX) has been steadily building a growth model that extends beyond traditional oral solid generics. That model increasingly leans on complex injectables, biosimilars, and specialized manufacturing capabilities that ca ...